Upstream / Downstream


Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: Product is assembled upon order. Please allow up to three business days for your product to be processed.

Research More. Spend Less.

Spend $650 or more and get 20% off*

(*Offer valid in the US only. Expires June 30, 2017)



Find answers on our FAQs page.


PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools



Western blot analysis of extracts from SH-SY5Y cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® Dopamine β-Hydroxylase (DBH) siRNA I (+), using Dopamine β-Hydroxylase (DBH) Antibody #8586 (upper) or β-Actin (13E5) Rabbit mAb #4970 (lower). The Dopamine β-Hydroxylase (DBH) Antibody confirms silencing of dopamine β-hydroxylase expression, while the β-Actin (13E5) Rabbit mAb is used as a loading control.

Learn more about how we get our images

Product Usage Information

CST recommends transfection with 100 nM SignalSilence® Dopamine β-Hydroxylase (DBH) siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

Product Description

SignalSilence® Dopamine β-Hydroxylase (DBH) siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit dopamine β-hydroxylase expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Dopamine β-Hydroxylase (DBH) is an enzyme of the copper type II ascorbate-dependent mono-oxygenase family. This enzyme forms homotetramers composed of two noncovalently bound disulfide-linked dimers and is found as both membrane-associated and soluble forms (1-3). The soluble form is present in the lumen of secretory granules (4) and is released from cells by exocytosis (5). DBH converts dopamine to noradrenaline (6). Deficiency in this enzyme causes a rare disease characterized by a complete absence of noradrenaline and adrenaline in plasma together with increased plasma dopamine levels (7). Orthostatic hypotension, the main symptom of DBH deficiency, can be alleviated by administration of dihydroxyphenylserine, a synthetic precursor of noradrenaline (8).

1.  Smith, W.J. and Kirshner, N. (1967) Mol Pharmacol 3, 52-62.

2.  Lagercrantz, H. (1976) Neuroscience 1, 81-92.

3.  Winkler, H. (1976) Neuroscience 1, 65-80.

4.  Laduron, P.M. (1975) FEBS Lett 52, 132-4.

5.  Weinshilboum, R.M. et al. (1971) Science 174, 1349-51.

6.  Kaufman, S. and Friedman, S. (1965) Pharmacol Rev 17, 71-100.

7.  Robertson, D. et al. (1986) N Engl J Med 314, 1494-7.

8.  Biaggioni, I. and Robertson, D. (1987) Lancet 2, 1170-2.

Entrez-Gene Id 1621
Swiss-Prot Acc. P09172

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.

SignalSilence® Dopamine β-Hydroxylase (DBH) siRNA I